ACD In Vitro Diagnostic Products

ACD is developing novel cancer diagnostic tests, including tests for:

 

• Head and Neck Cancer
• Circulating Tumor Cells (CTC)
• Cervical Cancer

 

Enabled by RNAscope’s unique technical capabilities, these tests could lead to clinical breakthroughs in cancer management.

 

• Human papillomavirus (HPV) has been established as an important cause of a subset of head and neck cancer. HPV-associated head and neck cancers are clinically distinct from those unrelated to HPV. RNAscope® allows detection of HPV biomarkers accurately in routine clinical tumor specimens, providing critical information for individualized treatment decision-making.
• Our CTC test can detect and characterize circulating tumor cells (CTCs) in blood. It can be used to monitor therapy response and disease progression, to determine patient prognosis, and to match targeted therapy to the molecular profile of CTCs.
• Our cervical cancer test can detect the existence of high grade precancerous lesions. It can be used for cervical cancer screening and triage of atypical squamous cells of undetermined significance.

 

As technical development for these tests are being completed, we are establishing collaborations for clinical validation and clinical trials. 

 

Please contact partnership@acdbio.com if interested in any of our clinical studies.